T-cell receptor like antibody for Rheumatoid arthritis - Karolinska Institute/Nextera
Latest Information Update: 26 Dec 2025
At a glance
- Originator Nextera
- Developer Karolinska Institute; Nextera
- Class Antibodies; Antirheumatics
- Mechanism of Action Immunosuppressants
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Rheumatoid arthritis